ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Cross Above 50 Day Moving Average – Here’s Why

Shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $108.64 and traded as high as $112.13. ProShares Ultra Nasdaq Biotechnology shares last traded at $109.77, with a volume of 14,721 shares traded.

ProShares Ultra Nasdaq Biotechnology Stock Performance

The firm has a market capitalization of $88.91 million, a P/E ratio of 20.68 and a beta of 1.22. The firm’s 50-day moving average is $108.64 and its 200 day moving average is $92.65.

Institutional Investors Weigh In On ProShares Ultra Nasdaq Biotechnology

Several institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. acquired a new stake in shares of ProShares Ultra Nasdaq Biotechnology in the second quarter valued at approximately $32,000. Citadel Advisors LLC acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology during the 3rd quarter worth about $307,000. Finally, Kaizen Financial Strategies grew its holdings in shares of ProShares Ultra Nasdaq Biotechnology by 4.7% in the 1st quarter. Kaizen Financial Strategies now owns 5,565 shares of the exchange traded fund’s stock valued at $483,000 after acquiring an additional 250 shares in the last quarter.

ProShares Ultra Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.